Not provided

3BNC117; CAS 1412902-17-0. Long-acting variants: 3BNC117-LS (teropavimab, GS-5423) and 3BNC117-LS-J

investigational

Biotherapeutic

bNAb targeting the CD4 binding site of gp120 on HIV-1 envelope

3BNC117 is a recombinant human IgG1 kappa bNAb cloned from an HIV-infected viraemic controller. It is a second-generation bNAb that binds the CD4 binding site on the HIV-1 envelope and, beyond neutralising virus, can engage Fc receptors to promote clearance of infected cells. It is the parent molecule of teropavimab (3BNC117-LS, GS-5423), the LS-modified long-acting variant that Gilead licensed from Rockefeller in January 2020 and is developing with zinlirvimab (10-1074-LS) and lenacapavir. The LS Fc modification roughly doubled half-life (median 2.8 versus 1.4 weeks in macaques), and teropavimab reached a mean half-life of 63.5 days after a 2,550 mg IV dose in people with HIV, which is what makes the six-monthly regimen feasible.

Not approved in any jurisdiction as of September 2026. The parent antibody 3BNC117 has been studied up to phase 2 in treatment and cure research. Its long-acting variant teropavimab (3BNC117-LS) is in phase 3 with zinlirvimab and lenacapavir, and holds US FDA breakthrough therapy designation for that combination (January 2025).

No marketing authorisation application identified for 3BNC117. Developed under US FDA IND 118225 (Rockefeller University); combination trials with albuvirtide conducted in China by Frontier Biotechnologies.